• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » H3 Biomedicine, Selvita collaborate

H3 Biomedicine, Selvita collaborate

September 23, 2013
CenterWatch Staff

H3 Biomedicine, a Cambridge, Mass.-based biopharmaceutical company specializing in  discovering and developing precision oncology treatments, and Selvita, a drug discovery company in Eastern Europe, have entered into a strategic collaboration to develop breakthrough precision medicines for cancers. The companies will seek to validate the importance and feasibility of several kinase targets in specific genetic contexts and to generate multiple novel drug candidates against those targets.

Recent advances in human cancer genomics have revealed novel target opportunities that will enable new approaches to developing cancer medicines. H3 Biomedicine has built extensive and proprietary target acumen. It also has implemented a set of unique tools and research engines in the areas of cancer genomics, bioinformatics and target validation to lend biological insight to genomic findings. These capabilities will help to accelerate its collaborative drug discovery and development efforts.

"Our goal at H3 Biomedicine is to—in a very focused way—utilize the genomic information from public and proprietary data sets to identify and validate highly relevant cancer genes and to develop effective therapies against those targets," said Markus Warmuth, M.D., president and chief executive officer, H3 Biomedicine. "Both H3 Biomedicine and Selvita value early validation of drug targets to achieve preclinical proof of concept followed by translation of these findings into novel therapies for targeted patient populations. This collaboration brings Selvita's kinase biology platform and medicinal chemistry capabilities together with H3's expertise in target validation, bioinformatics and genomics analysis.”

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing